Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.

Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E, Beukelman T, Patkar NM, Xie F, Saag KG, Herrinton LJ, Solomon DH, Lewis JD, Curtis JR.

JAMA. 2013 Mar 6;309(9):887-95. doi: 10.1001/jama.2013.1099.

2.

Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis.

Che H, Lukas C, Morel J, Combe B.

Joint Bone Spine. 2014 May;81(3):215-21. doi: 10.1016/j.jbspin.2013.07.009. Epub 2013 Aug 7. Review.

PMID:
23932722
3.

The risk of herpes zoster during biological therapy for psoriasis and other inflammatory conditions.

Adelzadeh L, Jourabchi N, Wu JJ.

J Eur Acad Dermatol Venereol. 2014 Jul;28(7):846-52. doi: 10.1111/jdv.12307. Epub 2013 Nov 4. Review.

PMID:
25081573
4.

A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data.

Chung CP, Rohan P, Krishnaswami S, McPheeters ML.

Vaccine. 2013 Dec 30;31 Suppl 10:K41-61. doi: 10.1016/j.vaccine.2013.03.075. Review.

PMID:
24331074
5.

Incidence and Prevention of Herpes Zoster Reactivation in Patients with Autoimmune Diseases.

Chakravarty EF.

Rheum Dis Clin North Am. 2017 Feb;43(1):111-121. doi: 10.1016/j.rdc.2016.09.010. Epub 2016 Oct 22. Review.

PMID:
27890168
6.

Does methotrexate increase the risk of varicella or herpes zoster infection in patients with rheumatoid arthritis? A systematic literature review.

Zhang N, Wilkinson S, Riaz M, Östör AJ, Nisar MK.

Clin Exp Rheumatol. 2012 Nov-Dec;30(6):962-71. Epub 2012 Dec 17. Review.

PMID:
23044005
7.

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis.

Ramiro S, Sepriano A, Chatzidionysiou K, Nam JL, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, Bijlsma JW, Burmester GR, Scholte-Voshaar M, Falzon L, Landewé RBM.

Ann Rheum Dis. 2017 Jun;76(6):1101-1136. doi: 10.1136/annrheumdis-2016-210708. Epub 2017 Mar 15. Review.

PMID:
28298374
8.

Tumor necrosis factor blockade and the risk of viral infection.

Kim SY, Solomon DH.

Nat Rev Rheumatol. 2010 Mar;6(3):165-74. doi: 10.1038/nrrheum.2009.279. Epub 2010 Feb 9. Review.

9.

Relation between disease modifying anti-rheumatic drugs and herpes zoster in rheumatoid arthritis.

Yamaoka K.

Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(3):181-9. doi: 10.2177/jsci.39.181. Review. Japanese.

10.

Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety.

Radovits BJ, Kievit W, Laan RF.

Drugs Aging. 2009;26(8):647-64. doi: 10.2165/11316460-000000000-00000. Review.

PMID:
19685931
11.

Varicella-zoster virus infection in rheumatoid arthritis patients in the anti-tumour necrosis factor era.

Cacciapaglia F, Zuccaro C, Iannone F.

Clin Exp Rheumatol. 2015 Nov-Dec;33(6):917-23. Epub 2015 Sep 22. Review.

PMID:
26394271
12.

Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients.

Ornetti P, Chevillotte H, Zerrak A, Maillefert JF.

Drugs Aging. 2006;23(11):855-60. Review.

PMID:
17109564
13.
14.

Association of infections and tuberculosis with antitumor necrosis factor alpha therapy.

Patkar NM, Teng GG, Curtis JR, Saag KG.

Curr Opin Rheumatol. 2008 May;20(3):320-6. doi: 10.1097/BOR.0b013e3282fa74f7. Review.

PMID:
18388525
15.

Vaccinations for rheumatoid arthritis.

Perry LM, Winthrop KL, Curtis JR.

Curr Rheumatol Rep. 2014 Aug;16(8):431. doi: 10.1007/s11926-014-0431-x. Review.

16.

Outcome of pregnancy and neonatal complications with anti-tumor necrosis factor-α use in females with immune mediated diseases; a systematic review and meta-analysis.

Komaki F, Komaki Y, Micic D, Ido A, Sakuraba A.

J Autoimmun. 2017 Jan;76:38-52. doi: 10.1016/j.jaut.2016.11.004. Epub 2016 Nov 30. Review.

PMID:
27913060
17.

The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases.

Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H.

Rheumatology (Oxford). 2014 Feb;53(2):213-22. doi: 10.1093/rheumatology/ket260. Epub 2013 Aug 14. Review.

18.

The role of specialty pharmacy drugs in the management of inflammatory diseases.

Mullican KA, Francart SJ.

Am J Health Syst Pharm. 2016 Jun 1;73(11):821-30. doi: 10.2146/ajhp150727. Epub 2016 Apr 28. Review.

PMID:
27126833
19.

Genetic and epigenetic predictors of responsiveness to treatment in RA.

Plant D, Wilson AG, Barton A.

Nat Rev Rheumatol. 2014 Jun;10(6):329-37. doi: 10.1038/nrrheum.2014.16. Epub 2014 Feb 18. Review.

PMID:
24535543
20.

[Risk of infection during treatment with tumor necrosis factor-alpha inhibitors].

Gaemperli A, Hauser T, Speck R.

Z Rheumatol. 2006 Feb;65(1):24-8, 30-1. Review. German.

PMID:
16421641

Supplemental Content

Support Center